Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacopan Pilot Study in IgA Nephropathy
NCT02384317Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of avacopan in immunoglobulin A nephropathy (IgAN), sponsored by Amgen. Primary endpoints: Change in Slope of First Morning Urinary Protein:Creatinine Ratio at 12 weeks, Number of Participants With Adverse Events and 1 more. Started Mar 2015; status: completed.
02
Drugs
avacopan
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02384317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384317.